Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Sunitinib in Advanced Solid Tumors
NCT06940349Phase 2Recruiting
- Sponsor
- Rabin Medical Center
- Start
- Oct 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palbociclib and sunitinib in solid tumor, sponsored by Rabin Medical Center. Started Oct 2021; status: recruiting.
02
Drugs
palbociclibsunitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06940349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940349.